Other languages BioDelivery Sciences International, Inc.

Equities

BDSI

US09060J1060

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Collegium Pharmaceutical, Inc. completed the acquisition of BioDelivery Sciences International, Inc. for approximately $670 million.	22-03-20
BioDelivery Sciences International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-09
Biodelivery Sciences International Announces ELYXYB Is Now Available in the U.S. for the Acute Treatment of Migraine	22-02-24
Collegium Pharmaceutical to Acquire BioDelivery Sciences in All-Cash Deal; Shares Jump	22-02-14
BioPharma Credit To Provide $650 Million Loan To Collegium For BioDelivery Acquisition	22-02-14
BioDelivery Sciences Shares Soar Amid Higher-Than-Average Volumes	22-01-24
BioDelivery Sciences International, Inc. Revises Earnings Guidance for the Full Year 2021	22-01-20
Insider Buy: Biodelivery Sciences International	21-11-22
Insider Buy: Biodelivery Sciences International	21-11-15
Insider Buy: Biodelivery Sciences International	21-11-09
Earnings Flash (BDSI) BIODELIVERY SCIENCES INTERNATIONAL Posts Q3 Revenue $41.1M, vs. Street Est of $42M	21-11-03
BioDelivery Sciences International, Inc. Provides Earnings Guidance for the Year 2021	21-11-03
BioDelivery Sciences International : Names John Golubieski Finance Chief	21-10-21
Dr Reddy Laboratories : Completes Sale of Rights for Migraine Treatment Drug in US, Canada	21-09-09
Sector Update: Health Care Stocks Advance Carried Higher by Biotech Companies	21-08-20
BioDelivery Sciences International : Gets $24 Million Contract From Veteran Affairs	21-08-20
BioDelivery Sciences International : to Buy US, Canadian Rights for Elyxyb Migraine Treatment From Dr. Reddy's	21-08-04
BioDelivery Sciences International : Earnings Flash (BDSI) BIODELIVERY SCIENCES INTERNATIONAL Reports Q2 Revenue $41.4M, vs. Street Est of $41.8M	21-08-04
Biodelivery Sciences International, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-04
BioDelivery Sciences International, Inc. Reiterates Its Earnings Guidance for the Full Year 2021	21-08-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioDelivery Sciences International, Inc.

Equities

BDSI

US09060J1060

Other languages

Filters